(Q50601108)

16 March 2018

title

Association between serum lipids and membrane fatty acids and clinical characteristics in patients with schizophrenia. (English)

1 reference

16 March 2018

1 reference

3

H Refsum

1 reference

16 March 2018

D K Solberg

1

1 reference

16 March 2018

H Bentsen

series ordinal

2

1 reference

16 March 2018

O A Andreassen

series ordinal

4

1 reference

16 March 2018

language of work or name

English

0 references

publication date

16 January 2015

1 reference

16 March 2018

Acta Psychiatrica Scandinavica

published in

1 reference

16 March 2018

volume

132

1 reference

16 March 2018

issue

4

1 reference

16 March 2018

page(s)

293-300

1 reference

16 March 2018

https://api.crossref.org/works/10.1111%2FACPS.12388

1 reference

Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Increasing mortality in schizophrenia: are women at particular risk? A follow-up of 1111 patients admitted during 1980-2006 in Northern Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Mortality and causes of death in schizophrenia in Stockholm county, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Excess mortality of schizophrenia. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

The metabolic syndrome and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Fatty acids and oxidative stress in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Oxidative stress: a link between cardiovascular disease and psychiatric illness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Severity of psychosis syndrome and change of metabolic abnormality in chronic schizophrenia patients: severe negative syndrome may be related to a distinct lipid pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Increases in triglyceride levels are associated with clinical response to clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Hypercholesterolaemia and its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Generalizability studies of the Global Assessment of Functioning-Split version.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Association of initial antipsychotic response to clozapine and long-term weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

A Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Free radicals, antioxidant defense systems, and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

The dietary pattern of patients with schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Metabolomic mapping of atypical antipsychotic effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

Impaired plasmalogens in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12388

21 January 2018

Identifiers

DOI

10.1111/ACPS.12388

1 reference

16 March 2018

1 reference

16 March 2018